Polypharmacology by design: FXR agonists (FXRa) and LTA4H inhibitors (LTA4Hi) hold therapeutic potential in non‐alcoholic steatohepatitis (NASH). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.